Peterson M E, Kintzer P P
Division of Endocrinology, Animal Medical Center, New York, New York, USA.
Vet Clin North Am Small Anim Pract. 1997 Mar;27(2):255-72. doi: 10.1016/s0195-5616(97)50030-1.
Mitotane (o,p'-DDD; Lysodren) is the drug most commonly used to treat dogs with pituitary-dependent hyperadrenocorticism. Although variations of the original protocol, suggested more than 20 years ago, have been reported, most clinicians still use an initial loading dose of mitotane followed by a weekly maintenance dose. Although a gratifying response to treatment is seen in most dogs, some dogs are neither easy nor straightforward to treat and present the practitioner with one or more therapeutic challenges, including failure to respond adequately, development of adverse effects, or development of relapse during treatment. Nevertheless, with careful management and follow-up, such problems can be overcome and a successful outcome achieved in most cases.
米托坦（邻对滴滴滴；Lysodren）是治疗垂体依赖性肾上腺皮质功能亢进犬最常用的药物。尽管有报道称20多年前提出的原始方案有所变化，但大多数临床医生仍采用米托坦初始负荷剂量，随后每周维持剂量。尽管大多数犬对治疗有令人满意的反应，但有些犬治疗起来既不容易也不简单，会给从业者带来一个或多个治疗挑战，包括反应不充分、出现不良反应或治疗期间复发。然而，通过仔细管理和随访，这些问题可以得到克服，大多数情况下能取得成功的结果。
